A major trial of a promising gene therapy for Duchenne muscular dystrophy has fallen short, but researchers say the lessons learned could pave the way for better, more effective treatments.

Gift 5 articles to anyone you choose each month when you subscribe. Toronto-headquartered Northleaf Capital Partners has emerged as a suitor for ProTen, the $1 billion-plus chicken farmer owned by ...